The last time the climb was featured in the Giro d'Italia Women was 30 years ago, on a 106km stage from Crocetta del Montello, when in 1995 a then rising Fabiana Luperini claimed her first stage win ...

Essentially, cereblon and its target proteins can change shape to form a complex with the cereblon, the target, and the ...

The findings from this landmark publication, featured on the cover of Science, have accelerated our ability to develop first-in-class medicines for historically intractable targets, validating the ...

State-backed Italian bank Banca Monte dei Paschi di Siena said its bid for rival Mediobanca would start on July 14 after the ...

From the very first winner in 1988, 'La Mamma Volante', to the latest 'amazing journey' that put Elisa Longo Borghini in the ...

With development having long since outpaced infrastructure improvements, Santa Rosa looks to creative funding sources to ...

Monte Rosa Therapeutics announced its first-quarter 2025 financial results and business updates, highlighting significant progress in its molecular glue degrader therapeutics portfolio. The ...

Monte Rosa has successfully completed GLP tox studies for MRT-8102, a first-in-class, NEK7-directed MGD for the treatment of inflammatory diseases driven by interleukin-1β (IL-1β) and the NLRP3 ...

Monte Rosa ended the quarter with $377 million in cash and equivalents, which is expected to fund operations into 2028. 3rd party Ad. Not an offer or recommendation by Investing.com.

Based on our data, Monte Rosa Therapeutics insiders have about 1.0% of the stock, worth approximately US$2.7m. I generally like to see higher levels of ownership.

Monte Rosa Therapeutics announced on March 20, 2025, that it will change the target indication for MRT-2359 to castration-resistant prostate cancer (CRPC). This appears to have caused a sharp ...

Monte Rosa Therapeutics (NASDAQ: GLUE) showcased a promising outlook during its Q4 2024 earnings call, highlighting a robust cash runway projected into 2028. The company maintains a strong ...